Gevokizumab: Phase I/II started

Xoma said NIH's National Eye Institute began an open-label, U.S. Phase I/II trial to evaluate 60 mg gevokizumab every 4 weeks for 16 weeks in 10 patients. Responders, defined as patients who experience a 2-step reduction on a 5-point scale from 0 to 4 or reach grade 0 in scleral inflammation in the study eye, will have the option to continue gevokizumab treatment for an additional 20 weeks. ...